AKT1 and prostate carcinoma: The PI3K-AKT-mTOR and AR pathways appear to play a particularly important role in counter-regulating each other in prostate cancers, such that inhibition of both pathways has recently been shown to result in synergistic cell killing in preclinical models [103].